Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.68 |
| ▸ | TTR | P02766 | 1/20 | 0.60 |
| ▸ | TRPV1 | Q8NER1 | 11/20 | 0.60 |
| ▸ | RBP4 | P02753 | 6/20 | 0.57 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27873708 | 0.84 | RBP4 (0.80) | AKR1C3RBP4 | |
| SCHEMBL9565850 | 0.82 | AKR1C3 (0.61) | AKR1C3TTRTRPV1RBP4 | |
| SCHEMBL20818495 | 0.81 | AKR1C3 (0.60) | AKR1C3TTRTRPV1RBP4HSD11B1 | |
| SCHEMBL31694435 | 0.81 | AKR1C3 (0.60) | AKR1C3TTRTRPV1RBP4HSD11B1 | |
| SCHEMBL1394196 | 0.80 | RBP4 (0.57) | AKR1C3TTRTRPV1RBP4 | |
| SCHEMBL13490136 | 0.80 | HSD11B1 (0.52) | AKR1C3TTRRBP4HSD11B1 | |
| SCHEMBL24937738 | 0.80 | AKR1C3 (0.66) | AKR1C3TTRTRPV1RBP4HSD11B1 | |
| SCHEMBL3095680 | 0.79 | HSD11B1 (0.76) | TRPV1RBP4HSD11B1 | |
| SCHEMBL19385669 | 0.79 | XPO1 (0.50) | AKR1C3TTRTRPV1RBP4 | |
| SCHEMBL30883144 | 0.79 | TTR (0.70) | AKR1C3TTRTRPV1RBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1701946-B1 | DERIVATIVES OF 1-PIPERAZINE- AND 1-HOMOPIPERAZINE-CARBOXYLATES, PREPARATION METHOD THEREOF AND USE OF SAME AS INHIBITORS OF THE FAAH ENZYME | SANOFI AVENTIS (FR) | 2007-12-19 | — | — | EP | claimed |
| EP-1714961-B1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-12-09 | — | — | EP | disclosed |
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2007-07-26 | — | — | US | disclosed |
| EP-1714961-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2006-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | CYP3A5, CYP3A43, TP53 | AKR1C3 397/4885TTR 3451/4885TRPV1 853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.